Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference
03/10/2022 - 10:00 AM
STONY BROOK, N.Y. --(BUSINESS WIRE)--
Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that Chief Executive Officer Dr. James A. Hayward will host a virtual fireside chat with the Company's covering analyst, Managing Director and Senior Research Analyst Jonathan Aschoff , on Monday, March 14, 2022 , at the 34th Annual ROTH Investor Conference .
Dr. Hayward , Beth Jantzen , chief financial officer, and Clay Shorrock , executive director of business development, will also host scheduled virtual one-on-one meetings with investors during the event.
To request a one-on-one meeting with Applied DNA, please email oneononerequests@roth.com or contact your Roth sales representative.
34th Annual Roth Investor Conference
Date: Monday, March 14, 2022
Time: 12:00 p.m. ET (9:00 a.m. ET )
Webcast: https://wsw.com/webcast/roth43/apdn/1811596
The fireside chat will be available for viewing and replay on the Investor Relations section of the Applied DNA website at www.adnas.com .
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ("PCR")-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a high-throughput turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn . Join our mailing list .
The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
View source version on businesswire.com : https://www.businesswire.com/news/home/20220310005505/en/
Investor Relations: Sanjay M. Hurry , 917-733-5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN
Source: Applied DNA Sciences, Inc.